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Abstract
Enveloped viruses need to fuse with a host cell membrane in order to deliver their genome into the host cell. While some
viruses fuse with the plasma membrane, many viruses are endocytosed prior to fusion. Specific cues in the endosomal
microenvironment induce conformational changes in the viral fusion proteins leading to viral and host membrane fusion. In
the present study we investigated the entry of coronaviruses (CoVs). Using siRNA gene silencing, we found that proteins
known to be important for late endosomal maturation and endosome-lysosome fusion profoundly promote infection of
cells with mouse hepatitis coronavirus (MHV). Using recombinant MHVs expressing reporter genes as well as a novel,
replication-independent fusion assay we confirmed the importance of clathrin-mediated endocytosis and demonstrated
that trafficking of MHV to lysosomes is required for fusion and productive entry to occur. Nevertheless, MHV was shown to
be less sensitive to perturbation of endosomal pH than vesicular stomatitis virus and influenza A virus, which fuse in early
and late endosomes, respectively. Our results indicate that entry of MHV depends on proteolytic processing of its fusion
protein S by lysosomal proteases. Fusion of MHV was severely inhibited by a pan-lysosomal protease inhibitor, while
trafficking of MHV to lysosomes and processing by lysosomal proteases was no longer required when a furin cleavage site
was introduced in the S protein immediately upstream of the fusion peptide. Also entry of feline CoV was shown to depend
on trafficking to lysosomes and processing by lysosomal proteases. In contrast, MERS-CoV, which contains a minimal furin
cleavage site just upstream of the fusion peptide, was negatively affected by inhibition of furin, but not of lysosomal
proteases. We conclude that a proteolytic cleavage site in the CoV S protein directly upstream of the fusion peptide is an
essential determinant of the intracellular site of fusion.
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Introduction
To achieve successful infection enveloped viruses need to fuse
with a host cell membrane to deliver the viral genome into the host
cell. Some viruses, such as herpes simplex virus, Sendai virus, and
human immunodeficiency virus, appear to be capable of direct
fusion at the plasma membrane after initial attachment [1–5].
However, the majority of enveloped viruses use endocytosis for
uptake and transport prior to fusion. Since endocytic cargo may
eventually end up in the destructive environment of the lysosome,
environmental cues are crucial to trigger viral fusion at the right
stage of trafficking. These triggers, which may include a decrease in
pH, changes in redox environment, and proteolytic activity [6–8],
induce conformational changes in the viral fusion proteins leading
to the merger of viral and host membranes. Two well-studied
viruses; influenza A virus (IAV) and vesicular stomatitis virus (VSV),
are known to undergo fusion upon exposure to low pH [9–12].
Other enveloped viruses, such as respiratory syncytial virus (RSV)
and Ebola virus, require proteolytic processing of their viral fusion
proteins in the endosomal system for fusion to occur [13–16].
Coronaviruses (CoVs) are enveloped, plus-strand RNA viruses
belonging to the family Coronaviridae in the order Nidovirales.
They are capable of infecting a wide variety of mammalian and
avian species. In most cases they cause respiratory and/or
intestinal tract disease. Human coronaviruses (HCoVs) are known
as major causes of the common cold (e.g. HCoV-229E and
HCoV-OC43). However, the emergence of new HCoVs of
zoonotic origin has shown the potential of CoVs to cause life-
threatening disease in humans as was demonstrated during the
2002/2003 SARS-CoV epidemics and more recently for MERS-
CoV in the Middle East [17,18]. The well-studied mouse hepatitis
virus (MHV) is often used as a safe model to study CoV infections.
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All CoV virions contain a canonical set of four structural
proteins. The viral genomic RNA is encapsidated by the
nucleocapsid protein (N) to form the helical nucleocapsid, which
is surrounded by the lipoprotein envelope, containing membrane
glycoprotein (M), the small envelope protein (E), as well as the
spike glycoprotein (S) (reviewed in [19]). Trimers of the CoV S
protein, a type I membrane protein belonging to the class I fusion
proteins, form the peplomers that protrude from the virion surface
[20]. The S protein can be divided into two functional subunits.
The amino-terminal S1 subunit contains the receptor-binding
domain; while the carboxy-terminal S2 subunit contains domains
required for fusion, including the fusion peptide (FP), heptad
repeat domains (HR) HR1 and HR2, and the transmembrane
(TM) domain.
Various entry routes have been described as being used by
different CoVs for infection of cells. Clathrin-dependent as well as
clathrin- and caveolae-independent entry pathways have been
reported for SARS-CoV [21,22]. Also feline infectious peritonitis
virus (FIPV) was suggested to enter via a clathrin- and caveolae-
independent endocytic route [23,24]. For the HCoV-229E a
caveolae-dependent endocytic uptake has been suggested [25].
Although the ability of MHV S proteins to cause cell-cell fusion at
a neutral pH was initially interpreted as an indication for fusion of
virions at the cell surface, more recent studies indicate the
requirement for clathrin-mediated endocytosis for entry of MHV
[26–29]. However, while some studies report that MHV strain
A59 is sensitive to lysosomotropic agents that affect endocytosis
[26], this is not the case according to others [27].
Proteolytic cleavage of the CoV S proteins appears to be
important for the induction of cell-cell fusion and/or virus entry
into host cells. Different cleavage sites have been identified for
different CoVs, the importance of which seems to differ for cell-cell
and virus-cell fusion. Some CoV S proteins, including that of
MHV strain A59, are cleaved at the S1/S2 boundary by furin(-
like) proteases during transport of the newly assembled virions
through the secretory pathway of the producer cell [30–33].
Inhibition of this S protein cleavage was shown to inhibit cell-cell
fusion, but not to affect entry of MHV strain A59 into host cells
[30,34,35]. MHV strain 2 contains an S protein that is not cleaved
at the S1/S2 boundary. Interestingly, although MHV strains 2
and A59 were both reported to enter via clathrin-mediated
endocytosis, entry of MHV 2 but not of MHV A59, was blocked
by inhibitors of low-pH activated cathepsin proteases [27,36].
Inhibitors of cathepsin proteases have also been shown to inhibit
entry of SARS-CoV and feline CoVs [23,37,38], while treatment
of cell-bound virus particles with different proteases was shown to
enhance virus entry and/or cell-cell fusion [27,34,39–45]. For
SARS-CoV and infectious bronchitis virus (IBV), it appears that a
proteolytic cleavage of the S protein at a more downstream
position than the S1/S2 boundary upon receptor binding is of
importance for cell entry [40,43,46–49].
In the present study we performed a detailed investigation of the
entry of different CoVs. Using siRNA gene silencing, we found
that the prototypic coronavirus MHV strain A59 (further referred
to as MHV) requires proteins known to be important for late
endosomal maturation and endosome-lysosome fusion for efficient
infection of cells. By using recombinant MHVs expressing reporter
genes as well as by applying a novel, replication-independent
fusion assay we confirmed the importance of clathrin-mediated
endocytosis and demonstrated that trafficking of MHV virions to
lysosomal compartments and processing of the S protein by
lysosomal proteases was required for productive entry to occur.
Our results indicate that a cleavage site in the S protein of CoVs
immediately upstream of the FP determines the site of fusion. In
agreement herewith FIPV, which requires processing by lysosomal
proteases, was also shown to depend on trafficking to lysosomes. In
contrast, MERS-CoV, which contains a minimal furin-cleavage
site consensus sequence in the S protein immediately upstream of
the FP, was negatively affected by inhibition of furin, but not of
lysosomal proteases.
Results
RNAi mediated gene silencing identifies endocytosis-
associated proteins to be important in MHV infection
In an automated, high-throughput RNAi screen [50] targeting
the druggable genome (approximately 7000 genes) a number of
proteins associated with endocytosis were found to be required for
efficient infection of HeLa cells with GFP-expressing MHV. To
validate these findings these proteins were subjected to a follow-up
analysis using siRNA-mediated gene silencing with oligonucleo-
tides from a different supplier than the one used for the initial
RNAi screen (Fig. 1A). The follow-up analysis included ACTR2
and ACTR3, two major constituents of the Arp2/3 complex
which are important for the formation of actin branches and cell
surface protrusions, as well as for the motility of several pathogens
inside host cells (reviewed in [51,52]). Also selected were the RAS-
related GTP-binding protein family members, RAB7A and
RAB7B, which have been shown to be involved in endosomal
maturation (reviewed in [53]). RAB7 interacts amongst others with
members of the homotypic fusion and vacuole protein sorting
(HOPS) tethering complex, involved in late endosome to lysosome
maturation. The HOPS subunit VPS39 (reviewed in [54]) was also
found to be a strong hit in the siRNA screen and therefore
selected. Other proteins included SNX1, involved in retrograde
transport of cargo between endosomes and the trans-Golgi
network (reviewed in [55]), VCL, inter alia involved in connecting
the Arp2/3 complex with integrins during actin polymerization
(reviewed in [56]), and the Ser/Thr-protein kinase PAK1, which is
activated by the Rho/Rac/Cdc42 family and is implicated in a
variety of downstream effects including modulation of the actin
cytoskeleton (reviewed in [57]).
Author Summary
Enveloped viruses need to fuse with a host cell membrane
in order to deliver their genome into the host cell. In the
present study we investigated the entry of coronaviruses
(CoVs). CoVs are important pathogens of animals and man
with high zoonotic potential as demonstrated by the
emergence of SARS- and MERS-CoVs. Previous studies
resulted in apparently conflicting results with respect to
CoV cell entry, particularly regarding the fusion-activating
requirements of the CoV S protein. By combining cell-
biological, infection, and fusion assays we demonstrated
that murine hepatitis virus (MHV), a prototypic member of
the CoV family, enters cells via clathrin-mediated endocy-
tosis. Moreover, although MHV does not depend on a low
pH for fusion, the virus was shown to rely on trafficking to
lysosomes for proteolytic cleavage of its spike (S) protein
and membrane fusion to occur. Based on these results we
predicted and subsequently demonstrated that MERS- and
feline CoV require cleavage by different proteases and
escape the endo/lysosomal system from different com-
partments. In conclusion, we elucidated the MHV entry
pathway in detail and demonstrate that a proteolytic
cleavage site in the S protein of different CoVs is an
essential determinant of the intracellular site of fusion.
Proteolysis-Dependent Coronavirus Entry via an Endo-/Lysosomal Pathway
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Transfection of HeLa cells carrying the receptor for MHV
(HeLa-mCC1a cells) with different siRNAs was followed by an
infection with GFP-expressing MHV (MHV-EGFPM) at low
multiplicity of infection (MOI), resulting in approximately 10–15%
infected cells under control conditions. After 8 h of infection cells
were collected and GFP expression by the replication of MHV was
analyzed by fluorescence-activated cell sorting (FACS). As controls
siRNAs silencing GFP and negative-control siRNAs were used. A
hit from the screen was considered as confirmed when transfection
with at least two out three independent siRNAs resulted in
significant reduction in MHV-driven GFP expression relative to
the negative-control siRNAs. siRNA-mediated gene silencing of
ACTR2 and ACTR3 resulted in reduced infections for all three
siRNAs, indicating that actin branching is important for MHV
infection (Figure 1A, dark orange). Also the importance of the
RAB7A, RAB7B and VPS39 proteins, involved in late-endosome
and late-endosome to lysosome maturation, for MHV infection
could be confirmed (Figure 1A, turquoise and light green). The
importance of SNX1, VCL and PAK1 for infection of HeLa cells
with MHV could not be confirmed (Figure 1A, grey). The latter
three genes were not studied any further. To validate our
transfection protocol and confirm the efficacies of the siRNAs at
the mRNA level, quantitative RT-PCR analysis was performed.
All siRNAs used reduced the corresponding mRNA levels with
75–95% (Figure 1B). siRNAs targeting RAB7A were shown to
inhibit the expression of a RAB7a-fusion protein (Figure S1 in
Text S1).
To confirm and extend our understanding of the role of
endocytosis in MHV entry we subsequently selected a number of
proteins known to be involved in either caveolae- or clathrin-
mediated endocytosis, actin- or microtubule-mediated transport,
as well as proteins associated with endosomal vesicles and
endosomal maturation, to be screened using the siRNA silenc-
ing-approach described above. Again, proteins were considered
important for infection with MHV when transfection with at least
two out three independent siRNAs resulted in significant reduction
in MHV-driven GFP expression relative to the negative-control
siRNAs. siRNA-mediated downregulation of proteins involved in
caveolae-mediated endocytosis revealed that CAV2, but not the
other proteins analyzed are important for infection with MHV
(Figure 1C, light blue). Downregulation of most proteins associ-
ated with clathrin-mediated endocytosis inhibited MHV infection,
Figure 1. RNAi-mediated downregulation of endocytosis-associated proteins affects MHV infection. A) Confirmation of endocytosis-
associated hits from druggable genome-wide siRNA screen. Gene silencing was performed using individual transfection of three different siRNAs per
gene in HeLa-mCC1a cells. Cells were infected with MHV-EGFPM at MOI = 0.5 for 8 h and analyzed by FACS for cell viability and virus replication. The
effect of downregulation of expression on MHV infection was studied for the actin cytoskeleton-associated proteins ACTR2 and ACTR3 (orange), late
endosomal proteins RAB7A and RAB7B (turquoise), HOPS complex sububit VPS39 (light green), ER/Golgi secretion-associated protein SNX1, Integrin/
Actin-associated protein VCL, and Serine/Threonine-protein kinase PAK1 (grey). Error bars represent SEM, n= 4. B) Confirmation of siRNA-mediated
reduction in mRNA levels. mRNA levels at 72 h post transfection were measured by qRT-PCR in comparison to non-transfected cells. Error bars
represent SEM, n = 3*3. C) The effect of the RNAi-mediated downregulation of an extended set of endocytosis-associated proteins on MHV infection.
Infection of MHV-EGFPM was analyzed after downregulation of proteins associated with caveolae-mediated endocytosis (light blue), clathrin-
mediated endocytosis (dark blue), early endosomes (cerulean), actin cytoskeleton (dark orange), microtubule cytoskeleton (orange), late endosomes
(turquoise), and late endosome-to-lysosome trafficking (light green) as described above. Error bars represent SEM, n = 3. A, C) Dotted lines show the
lower 95% confidence interval of the negative siRNA controls.
doi:10.1371/journal.ppat.1004502.g001
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including DNM1, DNM2, CLTC, and DAB2. siRNA-mediated
silencing of EPS15 or AAK1, accessory factors of clathrin-mediated
endocytosis, did not affect MHV replication (Figure 1C, dark blue).
Silencing of early endosome-associated genes (EEA1, RAB5A,
RAB5B, and RAB5C; Figure 1C, cerulean) each decreased
replication-mediated GFP expression. While downregulation of
MYO6, involved in actin-based motility, did not influence MHV
infection (Figure 1C, dark orange), our results indicate that the
microtubule-associated motility proteins DYNC1H1 and
DYNC2H1 are important for infection with MHV (Figure 1C,
orange). Silencing of NSF, required for transport from early to late
endosomes [58], or of the HOPS subunits VPS11 and VPS41,
which are involved in late endosome to lysosome maturation
(Reviewed in [54]), all resulted in severely reduced MHV infection
(Figure 1C, turquoise and light green, respectively).
Endocytosis-affecting agents indicate clathrin-mediated
endocytosis and endosome maturation to be important
in MHV infection
To further explore the endocytic route and factors involved in
MHV infection we determined the effect of inhibitors on MHV
infection. HeLa-mCC1a cells were treated with endocytosis-
affecting agents for 30 min and then infected with luciferase-
expressing MHV (MHV-EFLM; [59]) in presence of the
inhibitors, after which the inhibitors were kept present until cell
lysis. When cells were inoculated with MHV-EFLM in the absence
of inhibitors, the inhibitors were added to the cells at 2 h post
infection (hpi) to assess effects of inhibitors on post-entry steps. At
7 hpi cells were lysed and firefly luciferase expression levels were
determined.
Infection in the presence of the solvents dimethyl sulfoxide
(DMSO) and methanol (MeOH), as well as the known inhibitors of
MHV RNA synthesis Brefeldin A (BrefA, inhibitor of GBF1) [60]
and MG132 (proteasome inhibitor, probably also affects MHV
entry; [61]) were included as controls. MHV infection was not
affected by addition of the solvents, whereas both MG132 and
BrefA severely decreased luciferase expression regardless of the
time of addition. Inhibition of endosome maturation with
ammonium chloride (NH4Cl), Bafilomycin A1 (BafA1), or
Chloroquine (Chloq) severely diminished luciferase expression
when the inhibitors were added prior to infection. Much smaller
effects were observed when these drugs were added at 2 hpi,
indicating that the inhibitors mainly affect MHV entry (Figure 2,
deep sky blue). Similar effects were observed with known inhibitors
of clathrin-mediated endocytosis; Chlorpromazine (Chlopro),
Monensin (Mon), Dynasore, and Dyngo-4A (Dyngo). All these
compounds strongly decreased MHV replication-mediated lucif-
erase expression when added early but not when added at 2 hpi
(Figure 2, dark blue). The actin- and macropinocytosis-affecting
drug EIPA, which inhibits the Na+/H+ exchanger NHE1, led to
reduced luciferase expression both when added prior to and after
entry of MHV at 2 hpi. Actin cytoskeleton altering drugs
Latrunculin A (LatA), Jasplakinolide (Jasp), Cytochalasin B
(CytoB), and Cytochalasin D (CytoD), or the inducer of
microtubule depolymerization Nocodazole (Noc) only decreased
MHV infection when added early, indicating a role for the actin
and microtubule cytoskeleton in entry but not RNA replication
(Figure 2, dark orange and orange). Likewise U18666A, a
cholesterol transport-affecting agent, which also prevents matura-
tion of late endosomes [62], had a strong inhibitory effect on
MHV infection when added early (Figure 2, turquoise). Collec-
tively, these results indicate an important role for clathrin-
mediated uptake and for endosome- and endosome-to-lysosome
maturation for MHV infection.
Clathrin-mediated endocytosis and late endosomal
factors are required for MHV fusion
The time-of-addition experiments with the different inhibitors
indicated that particularly the entry step of the MHV infection
cycle is negatively affected by perturbation of clathrin-mediated
endocytosis or of endosome maturation. However, assays based on
reporter gene expression driven by virus replication do not allow
discrimination between virus entry and RNA replication when
analyzing siRNAs or agents that also affect RNA synthesis. To
unequivocally demonstrate the importance of clathrin-mediated
endocytosis and endosome maturation for MHV entry, we
therefore made use of a fusion assay we recently developed [63].
The assay is based on minimal complementation of defective b-
galactosidase (b-galactosidase DM15) with the short a-peptide
[64]. MHV-aN, a recombinant MHV containing an N protein
tagged with the a-peptide (aN), is used to infect DM152fragment
expressing target cells. Upon fusion of the virion with a host cell
membrane aN is released into the cytoplasm resulting in
complementation of the defective b-galactosidase thereby recon-
stituting a functional enzyme. Conversion of the non-fluorescent
substrate fluorescein-di-b-D-galactopyranoside (FDG) by b-galac-
tosidase into green fluorophores fluorescein (FIC) can be measured
by FACS or fluorescence microscopy (Figure S2 in Text S1).
To analyze the effect of RNAi-mediated gene silencing on
fusion, HeLa cells expressing the MHV receptor and the DM152
fragment (HeLa-mCC1a-DM15 cells) were transfected with
individual siRNAs and inoculated with MHV-aN at 72 h post
transfection. Before infection cells were pre-loaded with FDG by
hypotonic shock. After 100 min incubation of cells with virus at
37uC, cells were collected and the amount of FIC generated as a
results of enzyme complementation analyzed by FACS. The fusion
assay showed that silencing of neither CAV1 nor CAV2 affected
MHV fusion (Figure 3A, light blue), even though reduction of
CAV2 was shown to affect MHV infection (Figure 1C). However,
downregulation of clathrin-mediated endocytosis associated pro-
Figure 2. Endocytosis affecting agents indicate clathrin-
mediated endocytosis and endosome maturation to be
important in MHV infection. HeLa-mCC1a cells, inoculated with
MHV-EGFPM at MOI = 0.5, were treated with the different inhibitors
from 30 min prior to 8 h post inoculation (0–8 h) or from 2–8 h post
inoculation (2–8 h; hatched bars): ammonium chloride (NH4Cl),
Bafilomycin A1 (BafA1), Chloroquine (Chloq), Chlorpromazine (Chlopro),
Monensin (Mon), Dynasore, Dyngo-4A, EIPA, Latrunculin A (LatA),
Jasplakinolide (Jasp), Cytochalasin B (CytoB), Cytochalasin D (DytoD),
Nocodazole (Noc), MG132, Brefeldin A (BrefA), as well as solvents
dimethyl sulfoxide (DMSO) and methanol (MeOH). Infection was
determined by FACS and displayed relative to the infection level
observed in mock-treated cells (UNTR). Error bars represent SEM, n= 3.
doi:10.1371/journal.ppat.1004502.g002
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teins DNM2 and CLTC lead to strongly decreased fusion, as did
the lack of early endosome-associated factors RAB5B and RAB5C
(Figure 3A, dark blue and cerulean, respectively). Fusion was also
affected by RNAi-mediated reduction of actin cytoskeleton-
associated proteins ACTR2 and ACTR3 (Figure 3A, dark
orange), proteins known to be involved in late endosome (RAB7A,
RAB7B) and late endosome-to-lysosome maturation (VPS11,
VPS39, and VPS41) (Figure 3A, turquoise and light green).
The importance of clathrin-mediated endocytosis and endo-
some maturation for MHV fusion was confirmed by analysis of
endocytosis-affecting agents using the fusion assay. After pre-
loading with FDG, cells were pre-treated with the inhibitors for
30 min at 37uC, after which cells were inoculated with MHV-aN
in the presence of the agents, and analyzed by FACS as described
above. As controls we included protein synthesis inhibitor
cycloheximide (CHX), MHV fusion inhibitor peptide HR2
(HR2, [20]), MG132 and BrefA. Fusion of MHV was not affected
by the solvents or CHX, the latter confirming that this assay is
independent of RNA replication and protein synthesis. MHV
fusion was barely affected by replication inhibitor BrefA, whereas
MG132 had a clear negative effect, in agreement with the
conclusion drawn previously that MG132 inhibits entry of MHV
as well as RNA synthesis [61]. Inhibition of endosomal maturation
by NH4Cl, BafA1 and Chloq (Figure 3B, deep sky blue) or of
clathrin-mediated endocytosis by Chlopro, Mon, and Dynasore
(Figure 3B, dark blue) severely inhibited MHV fusion. Distur-
bance of the actin cytoskeleton by EIPA or by LatA, CytoB, or
CytoD reduced fusion by 75–80% (Figure 3B, dark orange), while
interference with microtubule polymerization by Noc had a
smaller effect (Figure 3B, orange). Late endosomal maturation
arrest caused by U18666A reduced fusion to approximately 10%
(Figure 3B, turquoise). In conclusion, the replication-independent
fusion assay confirmed the importance of clathrin-mediated
endocytosis and of endosome maturation for entry of MHV.
The data indicate that late endosome-to-lysosome maturation is
required for efficient entry and fusion.
Live-cell microscopy confirms co-localization, co-tracking
and fusion of MHV in endosomal compartments
To confirm the importance of endocytic uptake and the
association of MHV with endosomal compartments we performed
live-cell confocal microscopy. To this end, sucrose density
gradient-purified MHV virus was covalently labeled with the
low-pH resistant dye DyLight 488 (MHV-DL488). HeLa-mCC1a
cells were transfected with plasmids to express monomeric RFP
(mRFP) fusion proteins of RAB5, RAB7, or LAMP1. At 24 h post
transfection, MHV-DL488 was bound to cells at 4uC for 90 min.
Inoculation medium was replaced by warm medium containing
trypan blue, which immediately shifts the emission spectrum of
surface bound particles rendering them undetectable in the 505–
530 nm channel unless they get endocytosed [65]. Cells were
imaged using a spinning-disc confocal microscope acquiring z-
stacks in 30 s intervals over 10 min time frames from 10–70 min
post warming. Only low-level RFP fusion protein expressing cells
were selected for analysis. Interestingly, MHV particles newly
appeared even 60 min post warming, in agreement with the
notion that MHV enters in an unsynchronized manner (unpub-
lished results). Co-localization and co-trafficking of viruses with
endosomal compartments was assessed by detecting virus particles
based on size and intensity (green channel) and by measuring the
underlying intensity in the red channel (endosomal vesicles). MHV
virions were found to co-localize with all three endosomal
compartments (Fig. 4A). Whereas newly entering/appearing
particles were always co-localizing with RAB5 molecules, they
only associated with RAB7 and LAMP1 containing vesicles at later
time points.
To assess the association of MHV with endosomal vesicles
during the entry process more extensively, we manually tracked
the virus particles in the green channel and independently tracked
the endosomal vesicles in the red channel in x/y and z-direction. A
virion was categorized as associating with a certain endosomal
marker only if this co-localization was observed over at least four
sequential 30 s interval images. When the initial co-localization
was lost, but the virion did not disappear, this virion was classified
as associating/dissociating. Complete disappearance of a virus
particle (including in other z-stacks) while immediately previously
co-localizing with an endosomal marker was categorized as a
Figure 3. Clathrin-mediated endocytosis and late endosome-
to-lysosome trafficking is required for MHV fusion. A) Fusion
assay upon siRNA-mediated gene silencing. Three different siRNAs per
gene were transfected individually into HeLa-mCC1a-DM15. 72 h post
transfection, cells were pre-loaded with FDG by hypotonic shock. MHV-
aN was allowed to bind to the cells on ice at MOI = 20 for 90 min.
100 min post warming to 37uC, cells were collected and analyzed by
FACS. Fusion was determined relative to the number of FIC-positive
cells observed upon mock treatment of infected cells (UNTR). Error bars
represent SEM, n= 3. B) Fusion of MHV upon treatment of cells with
different inhibitors was studied as in A. Cells were pretreated with
ammonium chloride (NH4Cl), Bafilomycin A1 (BafA1), Chloroquine
(Chloq), Chlorpromazine (Chlopro), Monensin (Mon), Dynasore,
Dyngo-4A, EIPA, Latrunculin A, (LatA), Jasplakinolide (Jasp), Cytochala-
sin B (CytoB), Cytochalasin D (DytoD), Nocodazole (Noc), U18666A,
MG132, Brefelding A (BrefA), as well as with the solvents dimethyl
sulfoxide (DMSO) and methanol (MeOH), protein synthesis inhibitor
cyclohexamide (CHX), and MHV fusion inhibitor HR2 peptide (HR2) for
30 min at 37uC. The inhibitors were kept present during binding of
MHV-aN to cells and during warming to 37uC cells for 100 min. Fusion
was determined relative to the number of FIC-positive cells after mock
treatment (UNTR). Error bars represent SEM, n= 3.
doi:10.1371/journal.ppat.1004502.g003
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fusion event (Figures S3 and S4 in Text S1). When a viral particle
co-localized with endosomal compartments but did neither
dissociate nor fade during the 10 min acquisition period it was
classified as non-fusing. With this quantification method we
analyzed 75–100 virions in total for each of the endosomal
compartment types studied. The fraction of virions not fusing
during the acquisition period was consistently found to be at
around 10–15%. We observed that all of the entering MHV
particles initially co-localized with RAB5-positive early endosomal
vesicles and that most virions dissociated (were no longer co-
localized) after 4–6 min. Notably, it appeared that in these events
the RAB5 marker faded rather than moved away. Only a very
small percentage of virions were categorized as fusing while in
early endosomes. The number of fusion events was much higher
for virions co-localizing with RAB7 or LAMP1 (Figure 4B),
indicating that most virions fuse in late endosomes or lysosomes.
MHV infection depends on endosomal maturation
Our results so far indicate that most virions enter cells after
having accessed late endosomes/lysosomes. We hypothesized that
these compartments provide the environmental cues required for
productive virus-cell fusion. In order to analyze to what extent the
low pH in the endosomal system is required for entry of MHV, we
analyzed the inhibition of MHV entry at different concentrations
of BafA1. While high concentrations of BafA1 (as used for the
results shown in Fig. 2 and 3) affect endosomal maturation, at low
concentrations this inhibitor of vacuolar-type H+-ATPase only
elevates the pH of endosomal compartments but does not affect
endosomal trafficking per se [66]. We made use of that property
and tested the sensitivity of MHV to BafA1 side by side with the
control viruses VSV and IAV. VSV has been described to fuse at
pH 6.2 in early and/or late endosomes [9,11,12,67–69], while
IAV has been shown to fuse in late endosomes at an even lower
pH [9,10,70]. HeLa or HeLa-mCC1a cells were pretreated with
increasing concentrations of BafA1 for 30 min prior to infection
with reporter gene expressing viruses: VSV (VSVDG/FLuc-G*;
[71,72]), IAV (IAV-RLuc; [73]), or MHV (MHV-EFLM).
Luciferase expression levels indicated that infection of cells with
VSV and IAV is much more affected by BafA1, with an IC50
values of 0.80 and 0.63 nM, respectively, compared to MHV,
which displays a three to four fold higher IC50 of 2.34 nM
(Figure 5A).
Our results thus indicate that MHV is much less affected by
perturbation of the endosomal pH than VSV and IAV.
Nevertheless RNAi-mediated silencing of HOPS subunits and
treatment of cells with U1866A indicates that late endosome-to-
lysosome maturation is required for efficient entry. To confirm
Figure 4. Live-cell microscopy demonstrates co-localization
and co-tracking of MHV with endosomal vesicles and fusion of
MHV in these vesicles. HeLa-mCC1a cells transfected with plasmids
encoding RAB5-mRFP, RAB7-mRFP, or dsRed-LAMP1 were inoculated
with DyLight 488-labeled MHV. Live cell imaging was performed to
track internalized particles. A) Examples of MHV particles co-localizing
with RAB5-, RAB7-, and LAMP1-positive endosomal vesicles. Size bars
indicate 0.2 mM B) Virus particles that could be tracked were classified
as ‘fusing’ (Fusing) ‘associating/dissociating’ (Assoc/Dissoc), or ‘non-
fusing’ (Non-fusing) as described in the Materials and Methods section.
doi:10.1371/journal.ppat.1004502.g004
Figure 5. MHV infection depends on endosomal maturation. A)
HeLa-mCC1a cells were pretreated with increasing concentrations of
Bafilomycin A1 (BafA1) for 30 min and subsequently infected with
luciferase expressing MHV, VSV, or IAV in the presence of BafA1.
Infection levels were determined by assaying the luciferase activity in
cell lysates relative to lysates of infected cells that had been mock
treated. Error bars represent SEM, n = 3*3. B) Haploid cells (HAP1),
haploid cells lacking VPS33A (H1-DV33) or VPS33A-lacking haploid cells
retransfected with FLAG-tagged VLP33A (H1-DV33-fV33) were infected
with luciferase expressing MHV, VSV, or IAV. Cells were lysed at 7 h
(MHV and VSV) or 16 h post infection. Infection is displayed relative to
virus-driven luciferase expression levels in HAP1 cells. Error bars
represent SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g005
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and extend these observations, we made use of haploid HAP1 cells
lacking a functional HOPS complex resulting from lentiviral-
mediated knockout of the VPS33A subunit (H1-DV33 cells;
[74]).Both HAP1 cells and H1-DV33 cells were modified to stably
express the MHV receptor. As a control, the H1-DV33 cells were
in addition stably transfected with FLAG-tagged VPS33A (H1-
DV33-fV33). The different cells expressed similar levels of the
MHV receptor as determined by FACS analysis (Figure S5 in Text
S1). Expression of FLAG-VPS33A was confirmed by Western blot
(Figure S6 in Text S1). Functional reconstitution was confirmed by
confocal fluorescence imaging of lysosome localization (Figure S7
in Text S1). While in the knockout cells the lysosomes were
clustered, the lysosomes were dispersed again throughout the
cytoplasm in the FLAG-VPS33A re-transfected cells, as observed
in the HAP1 parental cells. The haploid cells were infected with
luciferase reporter gene-expressing MHV, VSV, or IAV at low
MOI. Cells were lysed at 7 (MHV and VSV) or 16 (IAV) hpi and
luciferase expression levels were determined. The lack of a
functional HOPS complex had no effect on VSV and IAV
infection; however, MHV infection was strongly reduced in the
knockout, but not in the re-transfected cells (Figure 5B). These
observations confirm the conclusion that late endosome-to-
lysosome maturation is required for efficient entry of MHV, a
characteristic that is not shared with the pH-sensitive VSV and
IAV.
Inhibition of lysosomal proteases prevents MHV fusion
Considering that MHV was much less affected by perturbation
of the endosomal pH than IAV and VSV while it requires
trafficking to lysosomes for efficient entry, we hypothesized that
entry might depend on cleavage of a viral protein by lysosomal
proteases. Hence we analyzed the extent to which different
protease inhibitors could inhibit MHV entry. Thus, HeLa-
mCC1a-DM15 cells were pretreated for 30 min with the different
inhibitors, after which the cells were inoculated with MHV-aN in
inhibitor-containing medium. Cells were collected, loaded with
FDG, and FDG conversion to FIC by complementation of b-
galactosidase upon viral fusion was assessed by FACS. Our results
indicate that most protease inhibitors tested (Fig. 6) hardly
inhibited fusion of MHV, if at all. Exceptions were AEBSF, which
has been shown to cause aggregation of early endosomal vesicles
[75], and a pan-lysosomal protease inhibitor (CPI; cystatin-
pepstatin inhibitor) capable of inhibiting the three major protease
family members found in lysosomes. Thus, by using CPI we
measured the combined effects of an endosomal papain-like
cysteine protease inhibitor (PLCP), an aspartyl protease inhibitor,
and an asparagine endopeptidase inhibitor (AEP) [76]. From these
results we conclude that inhibition of a broad range of endosomal
proteases efficiently blocks fusion of MHV, indicating that efficient
entry requires the activity of lysosomal proteases.
Introduction of a furin cleavage site immediately
upstream of the fusion peptide renders MHV
independent of lysosomal proteases
In general, class I fusion proteins require cleavage just upstream
of the FP to render them fusion competent [20,38,77]. However,
while the S protein of MHV is cleaved at the S1/S2 boundary
(Fig. 7A), no protease cleavage site has been identified close to the
fusion peptide. In view of the inhibition of MHV entry by the pan-
lysosomal protease inhibitor CPI and in analogy to other class I
fusion proteins, we hypothesized that an additional cleavage in the
S protein, immediately upstream of the FP, is necessary to induce
fusion. To test this hypothesis, we introduced an optimal furin
cleavage site (FCS) by substituting three amino acids by Arg
(AIRGRRRRRRR) immediately upstream of a highly conserved
Arg (indicated in bold) that occurs just N-terminal of the FP.
Recombinant MHV carrying this FCS in its S2 subunit was
designated MHV-S29FCS. (Figure 7A). Western blot analysis of
the S protein of a purified stock of this virus using an antibody
recognizing the S2 subunit showed no evidence of cleavage at the
newly introduced FCS (S29 site). Apparently, cleavage at this
position does not occur during virus production (Figure S8 in Text
S1). MHV carrying wild type or mutant S proteins displayed
similar growth kinetics (Figure S9 A and B in Text S1). Next we
analyzed whether the introduced FCS affected the sensitivity of the
recombinant MHV to CPI, which does not exhibit inhibitory
activity towards furin. Thus, HeLa-mCC1a cells were pretreated
with CPI for 30 min and subsequently infected with wild type S
(MHV-EFLM) or mutant S (MHV-S29FCS) containing viruses
expressing luciferase reporter genes in the presence of the protease
inhibitor. At 7 hpi the cells were lysed and viral-replication
dependent luciferase expression levels were determined. Introduc-
tion of the FCS resulted in the recombinant virus being no longer
sensitive to inhibition by lysosomal proteases (Figure 7B), probably
because the S protein is now cleaved by furin in an endocytic
compartment.
Furin inhibitor renders MHV-S29FCS sensitive to
endosomal maturation and decreases infection
To confirm that MHV-S29FCS is no longer dependent on
cleavage by lysosomal proteases, and to study its presumed
dependence on furin cleavage for entry, we analyzed the ability of
MHV-S29FCS to infect the haploid cells that lack VPS33A - and
thus the functional HOPS complex required for late endosome-to-
lysosome maturation - in the absence or presence of furin inhibitor
(FI). After pretreatment of MHV receptor-expressing HAP1, H1-
DV33, and H1-DV33-fV33A cells with furin inhibitor (FI) or mock
treatment, cells were inoculated with MHV-EFLM or mutant
virus MHV-S29FCS in presence or absence of FI. At 7 hpi the
cells were lysed and viral-replication dependent luciferase expres-
sion levels were determined. In agreement with previous results
Figure 6. Inhibition of lysosomal proteases prevents MHV
fusion. The MHV fusion assay was performed on HeLa-mCC1a-DM15
cells as described in the legend to Figure 3, in the presence of the
protease inhibitors CPI, AEBSF, Aprotinin, Leupeptin, Pepstatin A,
Camostat, and Phosphoramidon. As controls, cells were treated with
solvent DMSO, MHV fusion inhibitor HR2 peptide (HR2), and
lysosomotropic agent ammonium chloride (NH4Cl). Fusion was
determined relative to the number of FIC-positive cells after mock
treatment (UNTR). Error bars represent SEM, n= 3.
doi:10.1371/journal.ppat.1004502.g006
Proteolysis-Dependent Coronavirus Entry via an Endo-/Lysosomal Pathway
PLOS Pathogens | www.plospathogens.org 7 November 2014 | Volume 10 | Issue 11 | e1004502
(Fig. 5), infection with MHV carrying a wild type S was severely
reduced in cells lacking a functional HOPS complex and addition
of the FI did not alter this effect (Figure 8, red bars). In contrast,
infection with MHV-S29FCS was not decreased by the lack of a
functional HOPS complex. However, FI treatment had a clearly
negative effect on this virus, which was much more dramatic in the
absence of a functional HOPS complex in H1-DV33 cells
(Figure 8, blue). In conclusion, MHV-S29FCS lost the require-
ment for a functional HOPS complex in parallel with this virus
becoming insensitive to the pan-lysosomal protease inhibitor CPI.
In contrast to the virus with the wild type S, the mutant virus
became sensitive to inhibition of furin cleavage.
MHV-S29FCS fuses in early endosomes
To explore MHV-S29FCS entry requirements further we
assessed the effect of RNAi-mediated downregulation of early
and late endosome and HOPS complex associated genes.
Therefore, HeLa-mCC1a-DM15 cells were transfected with each
of three different siRNAs per gene for 72 h, after which they were
infected with wild type (MHV-EFLM) or mutant (MHV-S29FCS)
S protein containing MHV. At 7 hpi the cells were lysed and viral-
replication dependent luciferase expression levels were deter-
mined. As found previously (Fig. 1), infection with wild type S
protein carrying MHV was reduced after gene silencing of RAB5,
RAB7, VPS11, and VPS41 (Figure 9, red bars). On the other
hand, infection with MHV-S29FCS was significantly diminished
by downregulation of the early endosomal proteins RAB5B and
RAB5C, but not of the late endosomal proteins RAB7A and
RAB7B or the HOPS complex components VPS11 and VPS41
(Figure 9, blue bars). Consistently, infections with MHV carrying
wild type or mutant S protein were equally blocked by inhibitors of
clathrin-mediated endocytosis whereas the virus with the mutant S
(MHV-S29FCS) was much less sensitive to inhibitors of endosomal
maturation, including BafA1, or to perturbants of the actin
cytoskeleton (Figure S10 in Text S1). From these results we
conclude that introduction of a FCS immediately upstream of the
FP abolishes the requirement for trafficking of virions to lysosomes
and for processing by lysosomal proteases. The resulting virus,
which still depends on clathrin-mediated endocytosis, now requires
furin cleavage for efficient entry, the enzymes for which occur
earlier in the endocytic pathway [78].
Entry of other CoVs
Our results indicate that the protease cleavage site upstream of
the spike protein FP is an important determinant of the
intracellular site of fusion. To gain more insight into the putative
protease cleavage sites in the corresponding region of the S
proteins of other CoVs, we analyzed the sequence of this region in
several alpha, beta and gamma coronaviruses by performing
Figure 7. Introduction of a furin cleavage site just upstream of
the fusion peptide renders MHV independent of lysosomal
proteases. A) Schematic representation of the MHV spike protein. The
MHV S proteins are partially processed by furin at the S1/S2 boundary
(S1/S2) as indicated by the arrow. The furin cleavage site sequence at
this position (RRAHR) is shown. The signal sequence (SS) at the amino-
terminal end of the S1 subunit and the approximate positions of the
fusion peptide (FP), heptad repeat regions 1 and 2 (HR1 and HR2) and
the transmembrane domain (TM) in the S2 subunit are indicated. MHV-
S29FCS virus contains an optimal furin cleavage site (RRRRR) immedi-
ately upstream of the FP (S29, indicated by the arrow. B) Effect of pan-
lysosomal protease inhibitor (CPI) on MHV and MHV-S29FCS infection.
HeLa-mCC1a cells were pretreated with CPI for 30 min and inoculated
at MOI = 0.2 with luciferase expression cassette containing MHV-EFLM
or MHV-S29FCS in the presence of CPI, after which incubations were
continued in the presence of CPI until 7 hpi. Infection levels were
determined by measuring the luciferase activity in cell lysates relative to
mock-treated cells. Error bars represent SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g007
Figure 8. Furin inhibitor reduces infection with MHV-S29FCS
and renders the virus sensitive to endosomal maturation.
Haploid HAP1 cells (HAP1), haploid cells lacking VPS33A (H1-DV33) or
VPS33A-lacking haploid cells retransfected with FLAG-tagged VLP33A
(H1-DV33-fV33) were infected (MOI = 0.2) with MHV-EFLM (MHV-wt) or
MHV-S29FCS for 7 h. Where indicated, cells were treated with furin
inhibitor (FI). Infection levels were determined by measuring the
luciferase activity in cell lysates relative to mock-treated cells. Error bars
represent SEM, n= 3*3.
doi:10.1371/journal.ppat.1004502.g008
Figure 9. MHV-S29FCS fuses in early endosomes. siRNA-mediated
gene silencing was performed as described in the legend to Figure 1. At
72 h post transfection, HeLa-mCC1a were inoculated with MHV-EFLM or
MHV-S29FCS at MOI = 0.2 and incubated until 7 hpi. Infection levels
were determined by measuring the luciferase activity in cell lysates
relative to mock-treated cells. Dotted line shows the lower 95%
confidence interval of the negative siRNA controls. Error bars represent
SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g009
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ClustalW sequence alignment. The fusion peptide sequence was
found to be highly conserved amongst the different coronaviruses.
Also an Arginine residue immediately upstream of the predicted
fusion peptide is highly conserved with the exception of FIPV
(serotype II). Interestingly, MERS-CoV and IBV-Beaudette
contain a minimal furin cleavage site Arg-X-X-Arg just upstream
of the fusion peptide (Figure 10A). In analogy with the results
obtained with FCS-mutant MHV, we predicted that FIPV and
MERS-CoV would differ in their protease inhibitor sensitivity and
lysosomal trafficking requirements. To corroborate these findings,
we decided to analyze the entry of these two other coronaviruses.
To this end, HeLa cells expressing the FIPV receptor (HeLa-
fAPN cells) were subjected to siRNA-mediated downregulation of
late endosomal proteins RAB7A and RAB7B or of HOPS
complex subunits VPS11, VPS41, and VPS39, followed by
inoculation with luciferase expressing FIPV (FIPV-D3abcRL;
[79]). Infection with FIPV was significantly affected by siRNA-
mediated downregulation of proteins required for late endosome-
to-lysosome fusion (Figure 10B). Since the requirement for a
functional HOPS complex is indicative of fusion in lysosomes, as
we observed for MHV, we analyzed whether FIPV requires
processing by lysosomal proteases for efficient entry as well. The
results indicate that this is indeed the case as FIPV-driven
luciferase expression was diminished in the presence of the pan-
lysosomal protease inhibitor CPI (Fig. 10C). On the other hand,
infection with FIPV was not affected by FI.
As MERS-CoV carries a FCS in its S protein immediately
upstream of the FP, we hypothesized this virus not to require
trafficking to lysosomes and processing by lysosomal proteases for
efficient entry. To test this prediction, Huh-7 cells were pretreated
with FI or the pan-lysosomal protease inhibitor CPI for 30 min.
Cells were subsequently inoculated with MERS-CoV at a MOI of
0.1 in the presence of these inhibitors. At 8 hpi the cells were fixed
and the number of infected cells determined using immunocyto-
chemistry and wide-field microscopy. The results indicate that, in
contrast to wild type MHV and FIPV, but similarly to
recombinant MHV carrying a FCS immediately upstream of the
FP, infection with MERS-CoV is strongly inhibited by the FI but
not by CPI (Figure 11), indicating that MERS-CoV does not
require trafficking to lysosomes for efficient entry. Based on these
results we conclude that the cleavage site in the CoV S protein
immediately upstream of the FP is a key determinant of the
intracellular site of fusion.
Discussion
The results of this study provide an explanation for several,
apparently conflicting results from earlier studies with respect to
the process of MHV cell entry, particularly also regarding the
necessity of proteolytic cleavage of the CoV S protein. By using a
replication-independent fusion assay, we confirmed that MHV
entry requires clathrin-mediated endocytosis despite the well-
Figure 10. Entry of FIPV. A) Clustal W alignment of spike proteins from several coronaviruses. Displayed is the fusion peptide (boxed) and the area
upstream thereof. The area immediately upstream of the fusion peptide that contains the optimal FCS site (RRRRR) in MHV-S29FCS is also boxed. B)
siRNA-mediated gene silencing was performed as described in the legend to Figure 1. At 72 h post transfection, HeLa-fAPN cells were inoculated at
MOI = 0.2 with luciferase expressing FIPV-RLuc. At 7 hpi infection was determined by measuring the luciferase activity in cell lysates and displayed
relative to mock treated infection (inf). Error bars represent SEM, n = 3*3. Dotted line shows the lower 95% confidence interval of the negative siRNA
controls. C) HeLa-fAPN cells inoculated with FIPV-Rluc at MOI = 0.1 were treated with pan-lysosomal protease inhibitor (CPI) or furin inhibitor (FI) from
30 min prior to 7 h post inoculation (0–7 h) or from 2–7 h post inoculation (2–7 h; hatched bars). Infection levels were determined by measuring the
luciferase activity in cell lysates relative to mock-treated cells. Error bars represent SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g010
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known ability of the MHV S protein to cause cell-cell fusion at
neutral pH. We demonstrate that MHV particles traffic to and
fuse in lysosomes. Yet, MHV is much less sensitive to perturbation
of the low pH in the endo-/lysosomal system than low pH-
dependent control viruses VSV and IAV. Our results additionally
indicate that, for fusion to occur, the S protein of MHV requires
proteolytic cleavage immediately upstream of the FP, like other
class I fusion proteins. Efficient inhibition of MHV entry was only
observed using a pan-lysosomal protease inhibitor, and could not
be achieved using more specific protease inhibitors. Introduction
of an optimal furin cleavage site in the S protein immediately
upstream of the FP abolished the requirement for trafficking of
virions to lysosomes for fusion. However, this virus still required
clathrin-mediated uptake for efficient entry. Consistent with a
common mechanism for the entry of CoVs, FIPV, but not MERS-
CoV, the latter of which contains a furin cleavage site immediately
upstream of the FP, was shown to require trafficking to lysosomes
and processing by lysosomal proteases for efficient entry. Based on
these results we propose a model in which the cleavage site
immediately upstream of the FP is an essential determinant of the
intracellular site of CoV fusion (Figure 12).
The importance of clathrin-mediated endocytosis and endoso-
mal trafficking in the entry of MHV was revealed by several
complementary approaches. One of these was siRNA-mediated
gene silencing. Although - with the exception of RAB7A -
knockdown was not monitored at the protein level, we believe this
approach firmly demonstrates the importance of novel host factors
for several reasons. Validated siRNAs were used and the
experimental conditions were confirmed by analyzing the mRNA
expression levels of several genes by quantitative RT-PCR.
Furthermore, we made use of three independent siRNAs per
target gene, and a target was only classified as a hit when at least
two out three siRNAs showed the same phenotype. Importantly,
our findings were strengthened by targeting multiple proteins per
host cell pathway/complex, each time with very similar results.
Moreover, hits obtained with the replication-dependent reporter
assays were confirmed with our novel replication-independent
enzyme complementation entry assay. Also the use of recombinant
viruses differing only in their spike proteins enabled us to show that
inhibition of virus infection upon siRNA transfection resulted from
differences in virus entry and not virus replication. Finally, the
results obtained were corroborated by using a large panel of
inhibitors and by making use of haploid knockout cells, in which
late endosome-to-lysosome trafficking was inhibited.
Our results demonstrate that MHV requires endocytic uptake
for virus entry despite the S protein’s ability to induce cell-cell
fusion at neutral pH. Endocytic uptake is also required for a
mutant virus carrying a S protein with a FCS immediately
upstream of its FP, despite the relative insensitivity to high
concentrations of BafA1. Therefore, the ability of a virus to infect
cells in the presence of BafA1 does not necessarily imply virus
entry to occur at the cell surface. Also a recombinant MHV
carrying the spike protein of MHV-4 (MHV-JHM) was found to
enter via clathrin-mediated endocytosis (MHV-S4; Figure S10 in
Text S1) despite its ability to cause extensive cell-cell fusion [80–
82]. The ability of MHV to cause cell-cell fusion at neutral pH
while requiring endocytic uptake for virus-cell fusion suggests
different requirements and triggers for these two fusion processes.
Similarly, RSV was recently shown to enter cells after endocytic
uptake despite the ability of this virus to cause cell-cell fusion
[13].
The present study confirms and extends previous publications
on MHV entry via clathrin-mediated endocytosis [26,83]. Both
siRNAs downregulating clathrin-mediated endocytosis-associated
proteins, such as clathrin heavy chain (CLTC) and Dynamin 2
(DNM2), and agents affecting this uptake pathway (Chlopro,
Dynasore, Dyngo-4a) were capable of inhibiting infection with
MHV. Importantly, these findings could be confirmed in our
novel replication-independent virus-cell fusion assay, thereby
directly showing an involvement of clathrin-mediated endocytosis
in entry of MHV. Analysis of several accessory factors of clathrin-
mediated endocytosis showed that clathrin-mediated entry of
MHV strain A59 depends on clathrin-adaptor DAB2, but not on
EPS15 or AAK1. Previously, clathrin-mediated entry of MHV
strain 2 was also shown to be independent of EPS15 [83]. Based
on the use of inhibitors, it was earlier concluded that MHV entry
depends on cholesterol and lipid-rafts, which may be indicative of
caveolae-mediated endocytosis [84,85]. Although our replication-
dependent assays indicate a requirement for caveolin 2 (CAV2)
for infection, this protein was shown not to be involved in virus
entry using our fusion assay. Also depletion of other proteins
involved in caveolae-mediated endocytosis, including caveolin 1
(CAV1) and flotillins 1 and 2 (FLOT1 and FLOT2) did not affect
MHV infection or fusion. Interestingly, fusion of MHV was
severely inhibited by EIPA, an inhibitor of the Na+/H+
exchanger NHE1, which is regarded as a hallmark inhibitor of
macropinocytosis. Apparently, inhibition of virus entry by EIPA
does not prove by itself that a virus enters via this particular
pathway. EIPA has been reported to affect several other cellular
processes, including actin remodeling, internalization of lipid
rafts, distribution of endosomes, and even clathrin-mediated
endocytosis [86–90]. Similar to the results obtained with the
HeLa cells, also infection of murine LR7 cells was inhibited by
compounds interfering with clathrin-mediated endocytosis (Fig-
ure S11A in Text S1).
MHV virions require trafficking through the endocytic pathway
to lysosomes for efficient entry. Upon clathrin-mediated uptake
these virions are temporarily associated with early endosomes as
demonstrated by co-localization with RAB5 during live cell
imaging. Furthermore, the importance of early endosomes for
entry was indicated by siRNA-mediated downregulation of various
proteins associated with early endosomes (EEA1, RAB5A,
RAB5B, and RAB5C), which inhibited MHV infection, as well
as virus-cell fusion. However, only very few MHV particles
appeared to fuse in the early endosomes. Live cell imaging
indicated fusion largely to occur in late endosomes and/or
Figure 11. MERS-CoV requires cleavage by furin but not by
lysosomal proteases for infection. Huh-7 cells inoculated with
MERS-CoV were treated with furin inhibitor (FI) or pan-lysosomal
protease inhibitor (CPI) starting from 30 min prior to inoculation.
Numbers of infected cells was determined by immunocytochemical
staining. Error bars represent SEM, n= 3.
doi:10.1371/journal.ppat.1004502.g011
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lysosomes. Consistently, depletion of host proteins associated with
late endosome and late endosome-to-lysosome maturation
(RAB7A, RAB7B, and the HOPS complex subunits VPS11,
VPS33A, VPS39 and VPS41) or addition of U18666A, which
blocks late endosome-to-lysosome trafficking, were shown to
inhibit both infection and virus-cell fusion. The importance of
lysosomes for entry was confirmed by using knockout cells lacking
a functional HOPS complex (For a review on the HOPS complex
see [54]). Interestingly, in these cells lysosomes are clustered in a
perinuclear region of the cell rather than dispersed throughout the
cytoplasm. Complementation of the missing HOPS subunit
restored the normal lysosome distribution and entry of MHV
(Figure S7 in Text S1). The importance of late endosome-to-
lysosome trafficking for efficient entry was also observed in murine
cells (Figure S11C in Text S1) and for MHV-S4 carrying the S
protein of MHV-4 (JHM; Figures S10 and S12 in Text S1).
Corroborating the importance of trafficking of MHV virions
through the endocytic pathway, perturbation of endosome
maturation by the addition of inhibitory agents, such as
ammonium chloride, BafA1, Chloroquine, and Monensin inhib-
ited infection and fusion of MHV. Also the importance of the actin
and microtubule cytoskeleton - as demonstrated by the inhibition
of MHV entry by downregulation of the Arp2/3 complex factors
(ACTR2 and ACTR3), of the microtubule-associated transporter
dynein (DYNC1H1 and DYNC2H1), or by addition of actin- or
microtubule-affecting drugs - may be explained by the document-
ed involvement of the cytoskeleton in endosome maturation
(reviewed in [7]). Indeed, entry of MHV-S29FCS, which
presumably fuses in early endosomes, was much less affected by
actin-affecting drugs than that of MHV carrying wild type spike
proteins (Figure S10 in Text S1). However, we cannot exclude that
actin also plays a role in the clathrin-mediated uptake of MHV
particles, as has been observed for VSV and other pathogens that
depend on clathrin-mediated endocytosis (reviewed in [91]).
MHV particles require trafficking to the low pH environment of
lysosomes to achieve membrane fusion. Nevertheless, MHV was
much less sensitive to elevation of pH in the endo-/lysosomal
system by the addition of BafA1 than viruses known to fuse in early
or late endosomes (VSV and IAV). BafA1, an inhibitor of
vacuolar-type H+-ATPase was effective in blocking MHV entry
only at high concentrations, which are known to prevent
endosomal maturation in addition to the elevation of the pH
[66]. The absence of a functional HOPS complex, which is
required for late endosome-to-lysosome maturation, did not affect
Figure 12. Model of early and late coronavirus fusion.MHV and MHV-S29FCS are taken up by DAB2-dependent clathrin-mediated endocytosis
to end up in RAB5-containing early endosomes. The FCS of MHV-S29FCS is cleaved by furin or furin-like enzymes to allow fusion of the virus in early
endosomes. Trafficking of MHV from late endosomes to lysosomes (RAB7/LAMP1-positive compartments) is required for processing of MHV by
lysosomal proteases and viral fusion to occur. We propose that the sequence immediately upstream of the FP is a key determinant of the intracellular
site of fusion. MERS-CoV and FIPV enter cells via fusion in early endosomes or lysosomes, respectively. MERS-CoV, which contains a minimal FCS, is
inhibited by furin inhibitor (FI) but not by the pan-lysosomal protease inhibitor (CPI). The opposite holds true for FIPV. Based on this model, we
predict that IBV strain Beaudette and HCoV-NL63, which contain FCSs (Fig. 10), to fuse in early endosomes in a furin-dependent manner. Other CoVs
that do not contain a FCS at this position are predicted to fuse in lysosomes.
doi:10.1371/journal.ppat.1004502.g012
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infection of cells with VSV or IAV, while entry of MHV was
severely reduced. Thus, the low pH trigger that mediates entry of
VSV and IAV in the endosomal system of these cells, is not
sufficient to induce fusion of MHV. Other environmental cues,
present in lysosomes only, are apparently required to activate
conformational changes in the S protein leading to fusion. Indeed,
inhibition of the three major classes of proteases present in the
lysosome by CPI effectively prevented MHV fusion. Infection of
murine LR7 cells with MHV was also inhibited by CPI (Figure
S11B in Text S1). Strikingly, other inhibitors that affect members
of a single protease family had none or only little impact on MHV
fusion. These results are in consistence with a functional
redundancy of protease family members [47,76] and may explain
why previous studies using specific lysosome protease inhibitors
[27,92] failed to detect entry inhibition. Also, the inhibition of
MHV entry by MG132 may be explained by the known ability of
the proteasome inhibitor to negatively affect lysosomal proteases
[93–95], although we cannot exclude that MG132 affects entry by
its interference with lysosomal trafficking [96].
Our results indicate that cleavage of the S protein immediately
upstream of the FP is essential for CoV entry and determines the
intracellular site of fusion. Although we did not demonstrate
cleavage of MHV S at the FP proximal position directly, a recent
study found a cleaved form of the MHV S2 subunit to
correspond with the fusion-active form [49]. Furthermore,
introduction of an optimal FCS at the FP proximal position
abolished the entry inhibition by the pan-lysosomal protease
inhibitor whilst introducing a dependency on furin-related
enzymes. Consistent with the known presence of active furin in
early endosomes (reviewed in [78]) the mutant virus no longer
required trafficking to late endosomes/lysosomes for entry to
occur. However, in the presence of furin inhibitor, entry of this
mutant MHV was much more efficient in wild type cells than in
cells lacking a functional HOPS complex (Fig. 8), indicating that
under certain circumstances lysosomal proteases may play a role
in entry of this virus as well. Trafficking of virions to lysosomes
was shown to be also important for entry of FIPV, but not of
MERS-CoV, in agreement with the latter virus containing a
putative FCS immediately upstream of the FP. Correspondingly,
entry of FIPV was inhibited by the pan-lysosomal protease
inhibitor CPI but not by furin inhibitor, while the reciprocal held
true for MERS-CoV. The importance of S protein cleavage
downstream of the S1/S2 boundary and upstream of the FP for
infection has so far only been demonstrated for SARS-CoV and
IBV [40,43,46–48].
Based on the present study and on the work of others, we
conclude that cleavage at the FP proximal position is likely to be a
general requirement for CoV entry. With the exception of
possibly IBV, cleavage at this position does not appear to occur in
the virion-producing cell as it is not observed in released virions,
but in the target cell (this study; [40,43,47,48]). This suggests that
receptor binding or other environmental cues are necessary to
render the cleavage site accessible for proteolysis in the intact
virion. Also for several other viruses, including RSV [13] and
Ebola virus [16], cleavage of the fusion protein upon endocytosis
has been shown to be required for entry. Our results furthermore
show that cleavage at a FP-proximal position is an important
determinant of the intracellular site of fusion. The question
remains, however, why some CoVs evolved to fuse in early
endosomal vesicles while others require trafficking to lysosomes.
In view of the growing number of proteases that have been shown
to cleave CoV spike proteins [97], this question should probably
be studied in relation to the proteolytic enzymes available in the
CoV target tissues and cells in vivo.
Materials and Methods
Cells and viruses
Murine LR7 fibroblast [98] and feline FCWF cells (ATCC)
were used to propagate the recombinant MHV and FIPV viruses,
respectively. HEK293T, MDCK and Vero cells were used to
propagate pseudotyped VSVDG/Luc-G*, Renilla luciferase
expressing influenza A pseudovirus, or MERS-CoV, respectively,
as described previously [71,73,99]. Cells were maintained as
monolayer cultures in Dulbecco’s modified Eagle’s medium
(DMEM, Lonza), supplemented with 10% fetal bovine serum
(FBS). HeLa-ATCC cells stably expressing murine CEACAM1a
(HeLa-mCC1a) and LR7 cells were used for infection experiments
with MHV. HeLa-mCC1a cells stably expressing the deficient b-
galactosidase DM15 (HeLa-mCC1a-DM15) were used in the
fusion assay. Stable cell lines were generated using a Moloney
murine leukemia (MLV) retroviral vector. MLV was produced in
HEK293T cells by triple plasmid transfection of a transfer vector
containing the DM15 or mCC1a gene as well as a puromycin or
neomycin resistance marker gene, respectively, in combination
with expression vectors encoding the MLV Gag-Pol, and the VSV
spike protein G. Upon MLV transduction, stably transduced cells
were selected at 2 mg/ml puromycin and/or 0.5 mg/ml G418
(both Sigma), maintenance at 1 mg/ml puromycin and/or
0.5 mg/ml G418 in DMEM, supplemented with 10% FBS.
HAP1 cells and the VPS33A knockout derivative thereof (H1-
DV33) have been described previously [74]. H1-DV33 cells were
stably transfected with FLAG-tagged VPS33A (H1-DV33-fV33)
using MLV transduction as described above using a blasticidin
resistance marker gene in the transfer vector. Stably transduced
cells were selected and maintained at 5 mg/ml blasticidin. HAP1
cells and its derivatives were also provided with mCC1 as
described above to allow infection of these cells with MHV.
Chemicals
The MHV fusion inhibitor HR2 peptide has been described
before [100] and was synthesized by GenScript. The peptide was
diluted in Tris/HCl 50 mM, pH 7.8, 4 mM EGTA at 1 mM stock
solution and used at 10 mM final concentration. Fluorescein-di-b-
D-galactopyranoside (FDG) (AnaSpec) was dissolved in DMSO
resulting in a 20 mM stock solution. Stocks of 700 mM
cycloheximide (CHX, Sigma), 125 mM Bafilomycin A1 (BafA1,
Enzo Life Sciences), 140 mM Chloroquine (Chloq, Sigma),
120 mM Dynasore (Dyn, Enzo Life Sciences), 15 mM Dyngo-4a
(Dyngo, Abcam), 100 mM Ethylisopropyl amiloride (EIPA, Enzo
Life Sciences), 1 mM Nocodazole (Noc, Sigma), 1 mM Latruncu-
lin A (LatA, Enzo Life Sciences), 2 mM Jasplakinolide (Jasp,
Sigma), 20 mM Cytochalasin B (CytoB, Sigma), 20 mM Cyto-
chalasin D (CytoD, Sigma), 25 mM MG132 (Sigma), 1 mM
Brefeldin A (BrefA, Sigma), and 10 mM Furin Inhibitor I (FI,
Calbiochem) were prepared in DMSO and diluted 1:1000 in the
experiments, except when indicated otherwise. Stocks of 2 M
ammonium chloride (NH4Cl, Fluka), 5 mM AEBSF, 5 mM
Leupeptin, 1 mM Camostat, 1 mg/ml Aprotinin (all obtained
from Sigma) were prepared in H2O and used at 1:100 final
concentrations. 10 mM chlorpromazine (Chlopro, Sigma), and
20 mM U18666A (Enzo Life Sciences) were prepared in H2O and
used at 1:1000 final concentrations. Stocks of 6 mM Monensin
(Mon, Sigma) and 5 mM Phosphoramidon (Sigma) were prepared
in methanol (MeOH) and used at 1:1000 and 1:100 final
concentrations, respectively. 25 mg/ml cycloheximide (CHX,
Sigma) and 5 mM Pepstatin A (Sigma) were prepared in methanol
(EtOH) and used at 1:1000 and 1:100 final concentrations,
respectively. Solvents EtOH, MeOH, and DMSO were obtained
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from Sigma-Aldrich. A stock of 125 mM CPI in PBS was made
[76] and used at 5 mM final concentration.
Plasmids
All plasmids were constructed using conventional cloning
techniques. The DM15 gene was isolated from a DH5 E. coli
strain by DNA extraction and PCR. The gene was cloned into a
pCAGGS vector for (transient) expression and into a MLV-based
pQCXIP transfer vector (Clontech), resulting pQCXIP-DM15, for
the generation of stable cell lines. The gene encoding the MHV
receptor mCC1a [101] was cloned into pQCXIN, resulting in
pQCXIN-mCC1a. The RNA transcription vectors used for the
generation of recombinant MHV using targeted recombination
were generated using pMH54 derivatives [98,102]. pMH54
containing a GFP expression cassette between the E and M gene
was generated as described previously for firefly luciferase [59].
The transcription vector used to generate MHV-S29FCS
(pXHERLM-S29FCS+) was generated by site-directed mutagen-
esis, thereby changing the sequence encoding AIRGR immedi-
ately upstream of the FP into a RRRRR-encoding sequence in
vector pXHERLM [59] (GCA9ATC9CGA9GGG9CGT to
AGA9CGC9CGA9AGG9CGT). The transcription vector used to
generate MHV-S4 expressing firefly luciferase, was generated by
introducing the firefly luciferase expression cassette between the E
and M genes similarly as described previously [59] in a pMH54-
derived transcription vector that contains the gene encoding the S
protein of MHV-4 (MHV-JHM) [82]. This latter vector was kindly
provided by Susan Weiss.
Generation of recombinant/pseudo viruses
Recombinant MHV-EGFPM virus, containing a GFP expression
cassette between the E and the M gene, MHV-S29FCS, containing a
Renilla luciferase expression cassette between the E and the M gene
and a FCS at the FP-proximal position, andMHV-S4 containing the
spike gene of MHV-4 (JHM) and a luciferase expression cassette
were generated by targeted RNA recombination as described before
[98]. Briefly, donor RNA was generated from linearized pMH54-
derived transfer vectors described above, and electroporated into
FCWF cells infected with interspecies chimeric fMHV coronavirus
(an MHV-A59 derivative, in which the ectodomain of the spike
protein has been replaced by that of a feline coronavirus, thereby
changing host cell tropism). The electroporated FCWF cells were
seeded onto a monolayer of LR7 cells. After 24 h of incubation at
37uC, culture supernatant containing progeny viruses was harvested.
Genotypes of the recombinant viruses were confirmed after two
rounds of plaque purifications. Passage 3 stocks were used in
experiments. Generation of MHV-EFLM and MHV-ERLM,
containing a firefly or Renilla luciferase expression cassette between
the E and the M gene, andMHV-aN, containing a N protein tagged
with the a-peptide, has been described before [63,103]. Construction
of FIPV expressing Renilla luciferase was reported previously
[79].Recombinant VSVDG/FLuc-G* pseudovirus was generated as
described before [71]. Construction of IAV-WSN pseudovirus
expressing Renilla luciferase has also been described previously [73].
Viruses were stored in culture medium, supplemented with 25 mM
HEPES or upon sucrose cushion purification in TN buffer (10 mM
Tris-Cl, pH 7.4, 10 mM NaCl).
siRNA transfections
30,000 HeLa-mCC1a-(DM15) cells were seeded one day prior to
transfection in a 24-well dish. Using Oligofectamine (Life Technol-
ogies) reagent three independent, non-overlapping siRNAs (pre-
designed Silencer Select siRNAs from Ambion) per gene were
individually transfected into target cells according to the manufac-
turer’s instructions. Transfection mix for one well contained 2.5 ml
of 1 mM siRNA and 0.5 ml Oligofectamine in 50 ml OptiMEM
(Gibco). Transfection was done in 250 ml final volume of
OptiMEM. 4 hours post transfection 125 ml of DMEM, 30% FBS
were added. Cells were infected 72 hours post transfection.
qRT-PCR of siRNA-mediated gene knockdowns
HeLa-mCC1a cells were subjected to siRNA-mediated gene
knockdown as described above. At 72 hpi cells were harvested by
trypsinization, single-cell suspension counted, and collected by
centrifugation. Cellular RNA was extracted using the RNeasy
Mini Kit (Qiagen). mRNA levels of genes were analyzed by qRT-
PCR using a custom designed pair of specific primers to the gene
resulting in about 150 bp products. RNA levels were measured
using the GoTaq 1-Step RT-qPCR system (Promega) according to
the manufacturers’ instructions on a LightCycler 480 (Roche).
Expression levels were corrected for cell number and viability as
determined by the Wst-1 assay (Roche).
Virus infections
Cells were inoculated with MHV-EGFPM at MOI= 0.5 (15–
20% infected cells) in DMEM, 2% FBS, for 2 h at 37uC. The
inoculum was replaced by warm DMEM, 10% FBS. At 8 hpi, cells
infected with MHV-EGFPM were trypsinized and fixed in 4%
formaldehyde solution in PBS. Cells were washed and taken up in
FACS buffer (2% FBS, 0.05M EDTA, 0.2% NaN3 in PBS) and
GFP expression was quantified by FACS analysis on a FACS
Calibur (Benson Dickson) using FlowJo software. Of each sample
at least 10,000 cells were analyzed. HeLa, LR7, or HAP1 cells
were inoculated with luciferase expressing (pseudo)viruses (MHV-
EFLM, VSVDG/FLuc-G*, IAV-RLuc, MHV-S29FCS, or FIPV-
RLuc, MHV-EFLM-S4 (JHM)) at MOI=0.2, unless indicated
otherwise, in DMEM or IMDM (HAP1), supplemented with 2%
FBS at 37uC. At 2 hpi the inoculum was replaced by warm culture
medium containing 10% FBS. Cells were lysed at 7 hpi (MHV,
VSV, and FIPV) or 16 hpi (IAV) in passive lysis buffer (Promega).
Firefly luciferase expression was assessed using the firefly luciferase
assay system from Promega or using a homemade system (50 mM
tricine, 100 mM EDTA, 2.5 mM MgSO4, 10 mM DTT,
1.25 mM ATP, 12.5 mM D-Luciferin). Renilla luciferase expres-
sion was assessed using the Renilla luciferase assay system
(Promega). Light emission was measured on a Centro LB 960
luminometer. When indicated cells were transfected with siRNAs
prior to inoculation as described above. Luciferase expression
levels (in relative light units, RLU) were corrected for cell number
and viability as determined by the Wst-1 assay (Roche). When
indicated cells were treated with pharmacological inhibitors
starting at 30 min prior to or 2 h post inoculation. Huh-7 cells
were inoculated with MERS-CoV at a MOI of 0.1 in FBS-
containing DMEM. 8 h post infection, cells were fixed in 4%
formaldehyde in PBS. Cells were stained using rabbit anti-SARS-
CoV nsp4 antibodies that are cross-reactive for MERS-CoV,
according to a standard protocol using a FITC-conjugated swine-
anti-rabbit antibody. Number of infected cells was determined by
cell counts on a wide-field fluorescent microscope.
Fusion assay using b-galactosidase complementation
The b-galactosidase complementation fusion assay was per-
formed as described previously [63]. Briefly, cells were preloaded
with FDG substrate by incubation of adherent target cells with
2.5% FBS, 100 mM FDG, 50% PBS at room temperature. After
3 min incubation an excess of 5% FBS in PBS was added,
supernatant removed and replaced by growth medium. After a
recovery period of 30 min at 37uC, cells were (mock) treated with
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the different inhibitors for 30 min. MHV-aN virus was bound to
cells in DMEM with 2%FCS (in the absence or presence of
inhibitors) at a MOI= 20 for 90 min at 4uC to synchronize
infection, after which cells were shifted to 37uC for 2 h. Cells were
trypsinized and transferred to Eppendorf tubes, washed and
immediately analyzed by FACS. For experiments with protease
inhibitors the cells were loaded with FDG by hypotonic shock after
trypsination and collection of the cells. In this case, FDG loaded
cells were incubated on ice for 14 h before being analyzed by
FACS.
Fluorescent labeling of MHV
MHV wt virus was grown on LR7 cells and purified over a 20%
sucrose cushion in TN buffer by centrifugation at 110,000 rcf for
2.5 h. Supernatant was removed and pellet resuspended in 200 ml
TN buffer overnight on ice. Concentrated virus solution was
subjected to further purification on a Pfefferkorn gradient (10–
20%, 25–50%, 50% cushion). After spinning for 1 h at 150,000 rcf
a clear virus band was visible. The virus band was collected and
diluted in TN buffer. The virus was pelleted by centrifugation at
110,000 rcf for 1 h and resuspended in 200 ml 0.1M sodium
phosphate, 0.15M NaCl buffer pH 7.2 overnight on ice. The
purified virus solution was labeled using DyLight NHS 488
(Thermo Scientific) according to the manufacturer’s instructions.
Infectivity of the labeled virus was confirmed by TCID50 analysis
and qRT-PCR.
Live-cell microscopy
HeLa-mCC1a cells were seeded into 8-well glass-bottom
chambers to reach 60% confluency the next day. Plasmids
encoding mRFP-tagged RAB5A or RAB7A, or dsRed-LAMP1
[104] were transfected into the cells one day after seeding using
Lipofectamine 2000 (Life Technologies) according to the manu-
facturer’s instructions. 24 h after transfection MHV-DyLight488
was bound to cells on ice at MOI= 20 for 1.5 h in DMEM, 2%
FBS. The inoculum was removed and cells washed with cold PBS
to remove unbound virus. Warm imaging medium (DMEM
without phenol red, 10% FCS) containing 0.008% trypan blue
(Invitrogen) was added to the cell chambers. The cell membrane
impermeable trypan blue shifts the expression spectrum of cell
surface bound particles rendering them undetectable in the 505–
530 nm channel (described in [65]). Different low to medium RFP
expressing cells were imaged live at 37uC, 5% CO2 in 10 min time
frames from 10 min post warming up to 70 min in 30 s intervals
thereby acquiring z-stack images. Each slice was 0.30 mm in
thickness, averaging 12–14 slices per stack. For recording a Zeiss
Axio Observer Z1 inverse spinning-disk confocal microscope,
equipped with full box stage incubation, including CO2 (Pecon),
argon-krypton and helium-neon laser, two Photometrics Evolve
512 back-illuminated electron-multiplying charge-coupled-device
(EM-CCD) cameras, and 10061.46NA Oil alpha Plan Apochro-
mat objective was used. Fluorescence images were exported as.czi
files (Zeiss) and subsequently imported into Fiji (ImageJ, NIH).
Upon import into Fiji, color channels were split and saved as 8-
bit tagged image file format. Virus movements were manually
tracked in x/y or z direction in the green channel using the
MTrackJ plugin. Tracks were saved and subsequently loaded onto
the red channel. For each virus spot the area underlying a circle of
0.213 mm2 was measured for its gray mean value. Viruses were
considered colocalizing if the gray mean value reached 50% of the
maximum. Subsequently red and blue color channels were
merged, tracks imported and viruses classified using the viral
track. If the virus co-localized with the endosomal vesicle over at
least four sequential 30 s frames the virus was categorized as
associating. Viruses that, after initial co-localization, separated
from the vesicle were classified as ‘associating/dissociating’. If a
virus particle faded and disappeared (and could not be found in
other z-stacks) whilst co-localizing in previous intervals with an
endosomal vesicle it was categorized as ‘fusing’ (Figure S2 and S3
in Text S1). When a viral particle co-localized with endosomal
compartments but did neither dissociate nor fade during the
10 min acquisition period it was classified as ‘non-fusing’. With
this quantification method we analyzed 12 cells for RAB5 with 75
virions in total, 12 cells for RAB7 with 105 virions in total, and 16
cells for LAMP1 with 115 virions in total, acquired over three
independent experiments.
Sequence alignment
The sequences of MHV-A59 and MHV-S29FCS were based on
pMH54 sequencing results. Sequences for BCoV (GI: 18033975),
FIPV (GI: 556925469), HCoV-OC43 (GI: 530802591), HCoV-
HKU1 (GI: 306569687), SARS-CoV (GI: 89474484), MERS-
CoV (GI: 510937295), HCoV-229E (GI: 82780499), HCoV-NL63
(GI: 530802144), IBV-Beaudette (GI: 138186) were obtained from
NCBI. Alignments were performed over the entire length of the
spike proteins using MegAlign (Lasergene DNASTAR) using a
ClustalW alignment, gap penalty 10, gap length penalty 0.2, delay
divergent sequences 30%, DNA translation weight 0.5, protein
weight matrix: PAM series, DNA weight matrix: ClustalW.
Confirmation of siRNA-mediated knockdown of RAB7A
HeLa cells were co-transfected with mRFP-tagged RAB7A
similarly as described previously [60]. Briefly, 7’500 HeLa cells
were seeded one day prior to transfection in a 96-well plate. Using
Oligofectamine (Life Technologies) reagent three independent,
non-overlapping RAB7A siRNAs (pre-designed Silencer Select
siRNAs from Ambion) per gene were individually transfected into
target cells with the mRFP-RAB7A plasmid. Transfection mix for
one well contained 2.5 ml of 1 mM siRNA, 10 ng plasmid, and
0.5 ml Oligofectamine in 12.5 ml OptiMEM (Gibco). Transfection
was done in 62.5 ml final volume of OptiMEM. 4 hours post
transfection 125 ml of DMEM, 30% FBS were added. RFP
expression was analyzed 24 h post transfection using an EVOS
Cell Imaging System.
Immunostaining of HAP1 cells
Confluent HAP1, H1-DV33, and H1-DV33-fV33 cells and their
stably mCeacam1a expressing counterparts were detached using a
cell scraper, homogenized, and fixed. After 30 min incubation in
blocking buffer (3% BSA (Sigma), in PBS) for 1 h cells were
incubated in 1:100 N-CEACAM-Fc [80] antibody, washed, and
stained with 2ry AF488 goat-anti-rabbit antibody (Life Technol-
ogies). After washing cells were analyzed by FACS at 10,000 gated
single cells per sample.
Western blotting
HAP1 cells were trypsinized and collected by centrifugation at
350 rcf for 10 min. The pellet was resuspended in Laemmli sample
buffer containing 100 mM DTT, boiled for 5 min at 95uC and
subjected to electrophoresis in 10% acrylamide (Bio-Rad) gels.
Viruses were purified and concentrated over a 20% sucrose cushion
(in TN buffer) at 110,000 rcf. Pelleted virus was resuspended in TN
buffer overnight on ice. After addition of Laemmli sample buffer
(16 final concentration, 100 mM DTT), samples were boiled for
5 min at 95uC and subjected to electrophoresis in 7% acrylamide
(Bio-Rad) gels. Upon transfer to a nitrocellulose membrane
(Millipore), the presence of cellular and viral proteins was probed
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with antibodies against GM130 (rabbit pAb, Abcam), FLAG (HRP-
labeled mouse anti-FLAG mAb, Sigma) or the S2 subunit of MHV
A59 [105] (mouse anti-S2 mAb) diluted 1:1000. When necessary,
the blots were subsequently incubated with HRP-labeled rabbit
anti-mouse or swine anti-rabbit antibodies (both diluted 1:5000;
DAKO). Binding of HRP-labeled antibodies was visualized using
Amersham ECL Western blotting substrate (GE Healthcare Life
Sciences) according to the manufacturer’s instructions.
Immunofluorescence analysis of HAP1 cells
To image the localization of LAMP1 in HAP1, H1-DV33, and
H1-DV33A-fV33, cells the cells were seeded onto coverslips one
day prior to staining. Cells were fixed in 4% formaldehyde in PBS
for 15 min at RT, washed with PBS, and subsequently
permeabilized in PBS containing 0.1% Triton-X-100 for
10 min. Cells were incubated with antibody against LAMP1
(rabbit anti-LAMP1 pAb, 1:100 dilution; Abcam) in 3% BSA in
PBS followed by incubation with secondary antibodies coupled to
AF488, AF-568 phalloidin, and DAPI (all Life Technologies). The
samples were analyzed using a confocal laser-scanning microscope
(Leica SPE-II).
Growth curves of recombinant viruses
LR7 cells were infected at MOI= 0.1 or MOI= 4.0 with MHV-
ERLM or MHV-S29FCS in DMEM containing 2% FBS and
25 mM HEPES (infection medium). After 3 h of infection
supernatant was replaced by fresh infection medium and infection
was allowed to progress over a period of 24 h. Every 3 h a small
sample of the culture supernatant was collected and immediately
frozen. The samples were subsequently analyzed in TCID50
assays on LR7 cells and subjected to qRT-PCR analysis to
quantify virion production. Therefore viral RNA was extracted
from the samples using the QIAamp Viral RNA Mini Kit
(Qiagen). The relative amount of viral RNA present was
determined with a LightCycler 480 using LightCycler 480 RNA
Master Hydrolysis kit (Roche Applied Biosciences) and specific
primers and probe targeted against the MHV 1b gene by
comparison with a standard curve.
Gene identification numbers
Gene SwissProt ID
AAK1 Q2M2I8
ACTR2 P61160
ACTR3 P61158
CAV1 Q03135
CAV2 P51636
CLTC Q00610
DAB2 P98082
DNM1 Q05193
DNM2 P50570
DYNC1H1 Q14204
DYNC2H1 Q8NCM8
EPS15 P42566
FLOT1 O75955
FLOT2 Q14254
LAMP1 P11279
MYO6 Q9UM54
NSF P46459
PAK1 Q13153
RAB5A P20339
RAB5B P61020
RAB5C P51148
RAB7A P51149
RAB7B Q96AH8
SNX1 Q13596
VCL P18206
VPS11 Q9H270
VPS33A Q96AX1
VPS39 Q96JC1
VPS41 P49754
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